Repare Therapeutics Inc (RPTX)

Etorro trading 970x250
Repare Therapeutics Inc (RPTX) Logo

About Repare Therapeutics Inc

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. Address: 7210 Frederick-Banting, Montreal, QC, Canada, H4S 2A1

Repare Therapeutics Inc News and around…

Latest news about Repare Therapeutics Inc (RPTX) common stock and company :

Sum Up The Parts: SMMV Could Be Worth $43
16 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.43 per unit.

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
15 Nov, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November. Details are as follows:

Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
10 Nov, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
08 Nov, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 Nov, 2021 FinancialContent

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares. All common shares were sold by Repare. The total gross proceeds for the offering were approximately $101.2 million, before deducting underwriting commissions and offering expenses payable by Repare.

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
28 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner ...

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
28 Oct, 2021 FinancialContent

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare. All of the common shares are being offered by Repare. The offering is expected to close on November 1, 2021, subject to customary closing conditions. In addition, Repare has granted the underwriters a 30-day option to purchase up to an additional 600,000 of its common shares at the public offering price, less underwriting commissions.

Repare Therapeutics Announces Proposed Public Offering of Common Shares
27 Oct, 2021 FinancialContent

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares. All common shares to be sold in the proposed offering will be sold by Repare. Repare also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares at the public offering price, less underwriting commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
27 Oct, 2021 Yahoo! Finance

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
18 Oct, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 2nd Annual Precision Oncology Conference on Wednesday, October 20, 2021 at 12:30 p.m. Eastern Time.

KOMP's Holdings Imply 25% Gain Potential
12 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $76.80 per unit.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting
11 Oct, 2021 FinancialContent

Repare Therapeutics Inc(NASDAQ: RPTX) announced the presentation ofpreliminary Phase 1 monotherapy datafrom its ...

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference o
08 Oct, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (ataxia teleangectasia mutated kinase), at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass. & MONTREAL, October 08, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific syn

28 Stocks Moving In Friday's Mid-Day Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

45 Biggest Movers From Yesterday
08 Oct, 2021 FinancialContent

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. ...

Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference
07 Oct, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (“ANE Conference”) concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500:

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding week.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 Sep, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021. In addition, the Company will be hosting a Virtual Investor Webcast Event on Friday, October 8, 2021 at 5:00 p.m. ET.

Repare Therapeutics is Now Oversold (RPTX)
27 Sep, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
13 Sep, 2021 FinancialContent

Upgrades For Bank of America Corp (NYSE:BAC), Odeon Capital upgraded the previous rating of Hold to Buy. For the second ...

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
07 Sep, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company’s Board.

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference
02 Sep, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
12 Aug, 2021 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021.

Repare Therapeutics Inc (RPTX) is a NASDAQ Common Stock listed in , ,

970x250